Sutro Biopharma promotes Jane Chung to President and COO effective Dec 1, 2023

SUTRO BIOPHARMA, INC.

Jane Chung, previously Chief Commercial Officer, appointed President and COO, a newly created role.
New compensation includes $560k base salary, up to 50% bonus, 35k stock options, and 100k RSUs.
Chung previously served as President/GM of AstraZeneca Canada and VP of Immuno-Oncology at AstraZeneca.
Role focuses on operational excellence, strategic growth, and cross-functional alignment across R&D and portfolio.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jane Chung

President and Chief Operating Officer

STRO · SUTRO BIOPHARMA, INC.

Effective: 2023-12-01
Filed: November 21, 2023, 6:59 PM ET

On November 21, 2023, Sutro Biopharma, Inc. (the “Company”) announced the appointment of Jane Chung, currently the Company’s Chief Commercial Officer since August 2021, to the position of President and Chief Operating Officer of the Company, effective as of December 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jane Chung was appointed as President and Chief Operating Officer at SUTRO BIOPHARMA, INC..

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

On November 21, 2023, Sutro Biopharma, Inc. (the “Company”) announced the appointment of Jane Chung, currently the Company’s Chief Commercial Officer since August 2021, to the position of President and Chief Operating Officer of the Company, effective as of December 1, 2023.

View on SEC.gov

SUTRO BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-065482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.